Clinical Trial Update: BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery [Phase 2, Phase 3]

View source ↗

Summary

BMS-562247, studied in patients undergoing elective total knee replacement, completed its Phase 2/3 program for prevention of venous thrombosis and pulmonary em…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism

Drugs mentioned

• BMS-562247

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Venous Thrombosis, Pulmonary Embolism | Phase 2, Phase 3 | Status: COMPLETED